Companies to Research Antibody-Drug Conjugates (ADCs) to Address Cancers of High Unmet Need Collaboration to Utilize ImmunoGen's ADC Linker-Payload Technology Directed to Targets Identified by OBT; Each Company May Select a Number of Preclinical Programs for Internal Development OBT to Receive an
WALTHAM, Mass. --(BUSINESS WIRE)--Jun. 1, 2022-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on May 31, 2022 , the compensation committee of the Company’s Board of Directors approved grants of
Two Data Sets to be Presented at 2022 Annual Meeting Poster Highlighting Updated Data from SORAYA Characterizing Anti-Tumor Activity Selected for Best of ASCO ® Program: Tumor Reduction in 71.4% of Patients and Preliminary Median Overall Survival of 13.8 Months in High Folate Receptor Alpha
WALTHAM, Mass. --(BUSINESS WIRE)--May 25, 2022-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the following presentations by Company management at upcoming investor conferences will be webcast:
PDUFA Date is November 28, 2022 WALTHAM, Mass. --(BUSINESS WIRE)--May 23, 2022-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the US Food and Drug Administration (FDA) has accepted and filed the
WALTHAM, Mass. --(BUSINESS WIRE)--May 10, 2022-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Susan Altschuller , Chief Financial Officer, will present at the upcoming H.C.
Submitted BLA for Mirvetuximab Soravtansine Monotherapy to FDA Under Accelerated Approval Pathway; Commercial Preparations Underway Presented Results from Positive Pivotal SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer in Plenary Session at SGO Annual Meeting; Additional Efficacy and
WALTHAM, Mass. --(BUSINESS WIRE)--May 2, 2022-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on April 29, 2022 , the compensation committee of the Company’s Board of Directors approved grants of
WALTHAM, Mass. --(BUSINESS WIRE)--Apr. 21, 2022-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, May 6, 2022 to discuss its first
WALTHAM, Mass. --(BUSINESS WIRE)--Apr. 1, 2022-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on March 31, 2022 , the compensation committee of the Company’s Board of Directors approved grants of